| abstract |
The present invention allows patients with antineoplastic taxanes to treat patients suffering from diseases responsive to oral administration of antaxane with bioavailability enhancing agents. Preferably, paclitaxel is used as a taxane, and as preferred bioavailability enhancer, ciclosporin A is preferably used. In its invention, a taxane and a bioavailability promoter, preferably a cyclosporin, are used to prepare an oral medicament for the treatment of taxane-responsive diseases. The present invention also encompasses oral pharmaceutical compositions containing taxanes and bioavailability enhancers. HE |